Ipsen SA banner

During the last 3 months Ipsen SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 29% over this period (open performance analysis).

The last transaction was made on Mar 3, 2020 by Paul Sekhri , who bought 6.4k EUR worth of IPN shares.

Last Transactions:
Paul Sekhri
€+6.4k
Paul Sekhri
€+6.4k
Marc De Garidel
€-360.3k
Meek David
€-806.2k
David Meek
€-1.2m
Marc De Garidel
€-1.3m
Marc De Garidel
€-1.2m
Margaret Liu
€+43.4k
Carol Stuckley
€+36.7k
Benoît Hennion
€+168.4k
Benoît Hennion
€-102.1k
Marc De Garidel
€-2.6m
Marc De Garidel
€-381.6k
Marc De Garidel
€-1.1m
Marc De Garidel
€-360.3k
Philippe Robert-Gorsse
€-237.4k
Pierre Boulud
€-337.1k
Marc De Garidel
€+3m
Claude Bertrand
€-727.6k
Christophe Jean
€+30.7k
View All Transactions

During the last 3 months Ipsen SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 29% over this period (open performance analysis).

The last transaction was made on Mar 3, 2020 by Paul Sekhri , who bought 6.4k EUR worth of IPN shares.

Sold
0-3
months
0 EUR
0
3-6
months
0 EUR
0
6-9
months
0 EUR
0
9-12
months
0 EUR
0
Bought
0-3
months
No Insider Transactions
0
0 EUR
3-6
months
No Insider Transactions
0
0 EUR
6-9
months
No Insider Transactions
0
0 EUR
9-12
months
No Insider Transactions
0
0 EUR

Ipsen SA
Insider Trading Chart

Ipsen SA
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Ipsen SA
Last Insider Transactions

Global
Insiders Monitor

Ipsen SA
Glance View

Market Cap
13B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
140.62 EUR
Overvaluation 9%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett